Xencor, Inc.

NASDAQ:XNCR

Biotechnology

Healthcare
$34.39 -1.03%

-$0.13 today

Market cap
$2.58B
Beta
0.93
P/E (TTM)
-5.5
EPS (TTM)
-$2.29
52W Low $6.92High $18.69

Volume 0.87M

Average 0.80M

XNCR Investing Cash Flow

Net cash used in or generated by investments in assets, acquisitions, and securities.

Xencor, Inc.NASDAQ: XNCR

Investing Cash Flow · Q2 FY2026 · quarter ended Jun 2026

Investing cash flow grows, but more slowly than its trailing trend

Q2 FY2026 investing cash flow of $85.12M rose 110.3% year over year, behind the +467.4% change in trailing-twelve-month investing cash flow. Sequentially, it rose 219.1% from the prior quarter.

Context

  • Investing cash flow amounted to 111.5% of revenue in FY2025, up 104.3 pp from a year earlier.
  • Investing cash flow increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +110.3% toward the trailing-twelve-month pace of +467.4%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
$85.12M+219.1% QoQ
Last fiscal yearDec 2025
$139.99M+1878.3% YoY
LTMJun 2026
$197.64M+467.4% YoY
Investing Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+110.3%——
1 year+1878.3%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Investing Cash Flow history

USD · from the cash flow

Latest · FY2025
139.99M USD
Year-over-year change
+1878.3%

Investing Cash Flow vs competitors

How XNCR compares with its peers on the latest reported figures

  • Peers report in different currencies, so investing cash flow is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +467.4% is the highest of 8, against a peer median of -93.7%.
  • Investing cash flow amounts to 188.3% of revenue for XNCR, versus a peer median of 95.6%.
XNCR Competitors
Investing Cash Flow for XNCR and competitors
Company Period LTM YoY 3-year CAGR% of revenue
GMABGenmab A/SLTM Jun 2026$5.64B USD—+26.9%136.5%
NKTRNektar TherapeuticsLTM Jun 2026$844.4M USD-523.0%—1546.8%
XNCRXencor, Inc.LTM Jun 2026$197.64M USD+467.4%—188.3%
CLDXCelldex Therapeutics, Inc.LTM Sep 2026$84.56M USD-147.6%+32.5%75500.0%
MGNXMacroGenics, Inc.LTM Mar 2026$78.68M USD-158.5%—50.1%
IMMPImmutep LimitedFY2025A$38.53M AUD+83.3%+1089.2%764.0%
IMCRImmunocore Holdings plcLTM Mar 2026$21.83M USD-93.7%+76.9%5.7%
IPHAInnate Pharma S.A.FY2025€7M EUR-23.9%+55.1%251.2%
NRIXNurix Therapeutics, Inc.LTM Aug 2026$1.1M USD-83.6%+75.8%0.2%
ADAGAdagene Inc.LTM Jun 2024$447.24K USD——54.8%
CGENCompugen Ltd.LTM Dec 2025$0 USD—-6.8%0.0%
Peer median (excluding XNCR) —-93.7%+55.1%95.6%

Competitors are the stored peer set for XNCR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income82.63M(55.18M)(133.13M)(236.54M)(91.92M)
Depreciation & Amortization7.49M8.8M11.5M12.11M10.51M
Deferred Income Tax(18.97M)0000
Stock-Based Compensation36.98M48.91M053.28M43.23M
Change in Working Capital(102.6M)48.87M19.13M(40.4M)47.45M
Accounts Receivables(54.94M)36.86M19.83M(32.67M)28.73M
Inventory1.4M0000
Accounts Payables5.05M(3.91M)3.83M2.85M(3.95M)
Other Working Capital(54.11M)15.92M(4.53M)(10.57M)22.67M
Other Non-Cash Items(22.38M)(26.91M)24.58M9.36M(144.39M)
Operating Cash Flow(16.85M)24.49M(77.93M)(202.19M)(135.12M)
Capital Expenditures(15.98M)(43.4M)(18.45M)(6.1M)(3.15M)
Acquisitions (Net)(2.66M)0501K00
Purchases of Investments(509.6M)(387.93M)(782.91M)(595.05M)(298.9M)
Sales of Investments485.15M306.61M693.09M596.66M427.64M
Other Investing Activities(3.16M)90K0(3.38M)14.39M
Investing Cash Flow(46.25M)(119.73M)(110.57M)(7.87M)139.99M
Debt Repayment00000
Common Stock Issued28.92M05.39M201.26M9.96M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities14.12M5.7M183.33M(4.1M)(1.73M)
Financing Cash Flow43.04M5.7M188.72M197.15M8.23M
Effect of Forex Changes00(380K)00
Net Change in Cash(20.06M)(89.54M)(152K)(12.91M)13.1M
Free Cash Flow(32.83M)(18.92M)(96.37M)(208.29M)(138.27M)

Xencor, Inc.

NASDAQ:XNCR

Intrinsic Alpha fair value

Locked

Current Price

$34.39

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.